Table 2.
Primary outcomes: clinician ratings at baseline and 6- and 12-month follow-up for the 117 patients included in the primary analysis.
| Primary outcomes | Patient, n (%) | CGIa, mean (SD) | GAFb, mean (SD) | CGI; estimate, mean (95% CI)c | GAF; estimate, mean (95% CI)c | |||||||
| ATPd | ||||||||||||
|
|
Mean trajectory
|
|||||||||||
|
|
|
Baseline | 63 (100) | 3.9 (0.9) | 59.7 (10.8) | —e | — | |||||
|
|
|
Follow-up at 6 months | 61 (97) | 3.2 (1) | 62.4 (11.9) | — | — | |||||
|
|
|
Follow-up at 12 months | 45 (71) | 3.1 (1.1) | 63.7 (13) | — | — | |||||
|
|
Change from baseline | |||||||||||
|
|
|
6 months versus baseline | 61 (97) | −0.7 (1) | 2.8 (6.3) | −0.7 (−1.0 to −0.4) | 2.7 (1.1 to 4.4) | |||||
|
|
|
12 months versus baseline | 45 (71) | −0.8 (1.2) | 4.4 (8.7) | −0.8 (−1.1 to −0.5) | 4.7 (2.8 to 6.5) | |||||
| STPf | ||||||||||||
|
|
Mean trajectory
|
|||||||||||
|
|
|
Baseline | 54 (100) | 4.2 (1) | 57.6 (10.2) | — | — | |||||
|
|
|
Follow-up at 6 months | 49 (91) | 3.3 (1) | 60.7 (11.0) | — | — | |||||
|
|
|
Follow-up at 12 months | 38 (70) | 3.0 (1) | 61.8 (12.2) | — | — | |||||
|
|
Change from baseline | |||||||||||
|
|
|
6 months versus baseline | 49 (91) | −0.9 (1) | 2.9 (6.4) | −0.9 (−1.2 to −0.6) | 3.3 (1.4 to 5.1) | |||||
|
|
|
12 months versus baseline | 38 (70) | −1.2 (1) | 5.1 (6.3) | −1.2 (−1.5 to −0.9) | 5.2 (3.2 to 7.2) | |||||
| ATP versus STP, difference at baseline | — | — | — | −0.3 (−0.6 to 0.1) | 0.9 (−2.1 to 4) | |||||||
| ATP versus STP, difference at follow-up at 6 months | — | — | — | −0.1 (−0.4 to 0.3) | 0.4 (−2.8 to 3.5) | |||||||
| ATP versus STP, difference at follow-up at 12 months | — | — | — | 0.1 (−0.3 to 0.5) | 0.4 (−2.9 to 3.7) | |||||||
| ATP versus STP, difference in follow-up at 6 months versus baseline differences | — | — | — | 0.2 (−0.2 to 0.6) | −0.6 (−3.1 to 1.9) | |||||||
| ATP versus STP, difference in follow-up at 12 months versus baseline differences | — | — | — | 0.4 (−0.04 to 0.8) | −0.5 (−3.3 to 2.2) | |||||||
aCGI: Clinical Global Impression scale; severity of illness; range 1-7, higher is more severe.
bGAF: Global Assessment of Functioning; range 0-100, higher is better functioning.
cFrom mixed-effects linear regression models adjusted for study site, consulting psychiatrist, and language of the interview, as well as clustering due to patient. The model for the Global Assessment of Functioning was further adjusted for clustering by the referring physician.
dATP: asynchronous telepsychiatry.
eNot available.
fSTP: synchronous telepsychiatry.